• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Teva, Biogen reveal positive results for MS drugs

Teva, Biogen reveal positive results for MS drugs

April 13, 2011
CenterWatch Staff

Teva and Biogen Idec have presented late-stage data on their respective oral offerings for the treatment of multiple sclerosis (MS), according to Pharma Times.

Laquinimod, made by Teva who partnered with Active Biotech, met the endpoint in the late-stage 1106-patient ALLEGRO trial, demonstrating a 23% reduction in annual relapse rates (AAR) compared to placebo. The study also showed that patients had a 36% reduction in any progression of disability and a 33% decrease in brain atrophy, compared to placebo. Elevated liver enzymes, relative to placebo, were present in some patients, but these increases did not lead to liver problems.

Teva and Active Biotech plan to file for regulatory approval of laquinimod once results from the phase III BRAVO trial are released.

Biogen presented positive results from DEFINE, the first of two phase III trials evaluating BG-12 (dimethyl fumarate) as an oral monotherapy in people with relapsing-remitting MS. Results showed that 240 mg of BG-12, administered either twice or three times a day, met the primary study endpoint, demonstrating a reduction in patients who relapsed at two years compared with placebo. Additional analyses of DEFINE are ongoing.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing